We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Simple Blood Test Prior to CAR T-Cell Therapy Could ID Patients at Risk for Neurotoxicity

By LabMedica International staff writers
Posted on 23 Sep 2022
Print article
Image: Blood test before CAR T-Cell treatment can identify patients likely to develop neurotoxicity (Photo courtesy of Unsplash)
Image: Blood test before CAR T-Cell treatment can identify patients likely to develop neurotoxicity (Photo courtesy of Unsplash)

Neurologic complications are common following treatment with chimeric antigen receptor (CAR) T cells, with an estimated 40-60% of patients developing immune effector cell–associated neurotoxicity syndrome (ICANS). Neurotoxic symptoms typically occur 3-9 days after infusion. While these side effects are generally low-grade, morbidity and mortality can occur with higher grade symptoms. Encephalopathy, aphasia and cerebral edema can occur. Now, a small study has demonstrated that a simple blood test before treatment can help identify patients who may be more likely to develop this adverse side effect.

Elevated levels of a protein called neurofilament light chain (NfL) have been observe in multiple neurodegenerative and neuroinflammatory diseases, suggesting to researchers at the Washington University School of Medicine in St. Louis (St. Louis, MO, USA) that it could be a biomarker for ICANS in patients set to undergo CAR T-cell treatment. The retrospective study included 30 patients out of which 12 patients were women and 18 were men. The median age was 64. NfL levels were measured at baseline (prior to lymphodepletion), during lymphodepletion, and days 1, 3, 7, 14 and 30 after infusion. Elevated NfL levels prior to lymphodepletion were markedly higher among patients who developed ICANS - 87.6 pg/mL for any ICANS vs. 29.4 pg/mL without ICANS (P < .001). Sensitivity and specificity of the test were 91% and 95%, respectively. NfL levels remained elevated through day 30.

“Our study suggests that some patients receiving CAR-T cell therapy have previously undetected damage to neurons present at baseline, before we even begin preparing them for this treatment,” lead author Omar H. Butt, MD, PhD, an instructor in oncology at the Washington University School of Medicine, said in a press release. “We don’t know the origin of this damage, but it appears to predispose them to developing neurotoxic complications. If we understand who is at risk of these complications, we can take early steps to prevent it or reduce the severity.”

Related Links:
Washington University School of Medicine in St. Louis 

New
Gold Supplier
Creatinine/eGFR Meter
Nova Max Pro
New
Influenza A+B Test
Anyplex FluA/B Typing Real-Time Detection
New
Automated Immunoassay Analyzer
cobas e 411
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation

Print article
IIR Middle East

Channels

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.